Nanomedicines Innovation Network

Dr. Daniel J Renouf, MD

Claim this profile

BC Cancer - Vancouver

Studies Pancreatic Cancer
Studies Breast Cancer
7 reported clinical trials
15 drugs studied

Area of expertise

1

Pancreatic Cancer

Daniel J Renouf, MD has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage III
Stage IV
2

Breast Cancer

Daniel J Renouf, MD has run 2 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
PR positive
HER2 negative

Affiliated Hospitals

Image of trial facility.

BC Cancer - Vancouver

Image of trial facility.

BC Cancer Agency

Clinical Trials Daniel J Renouf, MD is currently running

Image of trial facility.

Genetic Testing

for Pancreatic Cancer

The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.

Recruiting

1 award

N/A

4 criteria

Image of trial facility.

Atezolizumab

for Cancer

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.

Recruiting

1 award

Phase 2

10 criteria

More about Daniel J Renouf, MD

Clinical Trial Related

1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Daniel J Renouf, MD has experience with

  • Tumour DNA And Proteins
  • Anti-hyperglycemic Treatments (Metformin, Insulin, GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors)
  • Continuous Glucose Monitor (CGM)
  • CFI-402257
  • BMS-986253
  • Ipilimumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Daniel J Renouf, MD specialize in?

Is Daniel J Renouf, MD currently recruiting for clinical trials?

Are there any treatments that Daniel J Renouf, MD has studied deeply?

What is the best way to schedule an appointment with Daniel J Renouf, MD?

What is the office address of Daniel J Renouf, MD?

Is there any support for travel costs?